161 related articles for article (PubMed ID: 30602026)
21. Zinc ions increase GH signaling ability through regulation of available plasma membrane-localized GHR.
Li R; Hui J; Luo G; Hong P; Li L; Yang Y; Zheng X; Lan H
J Cell Physiol; 2019 Dec; 234(12):23388-23397. PubMed ID: 31173363
[TBL] [Abstract][Full Text] [Related]
22. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
23. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
24. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Paisley AN; Trainer P; Drake W
Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
[TBL] [Abstract][Full Text] [Related]
25. Insights from growth hormone receptor blockade.
Muller AF; van der Lely AJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
[TBL] [Abstract][Full Text] [Related]
26. SCF(TrCP) acts in endosomal sorting of the GH receptor.
van Kerkhof P; Westgeest M; Hassink G; Strous GJ
Exp Cell Res; 2011 Apr; 317(7):1071-82. PubMed ID: 21195069
[TBL] [Abstract][Full Text] [Related]
27. Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells.
Meinhardt U; Eblé A; Besson A; Strasburger CJ; Sraer JD; Mullis PE
Kidney Int; 2003 Aug; 64(2):421-30. PubMed ID: 12846737
[TBL] [Abstract][Full Text] [Related]
28. The place of pegvisomant in the management of acromegaly.
Parkinson C; Trainer PJ
Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
[TBL] [Abstract][Full Text] [Related]
29. [Growth hormone receptor antagonists: potential indications].
Muller AF; Janssen JA; de Herder WW; van der Lely AJ
Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
31. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
32. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
33. GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract][Full Text] [Related]
34. Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains.
van Kerkhof P; Sachse M; Klumperman J; Strous GJ
J Biol Chem; 2001 Feb; 276(6):3778-84. PubMed ID: 11042179
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
36. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
[TBL] [Abstract][Full Text] [Related]
37. Metabolic effects of GH antagonism in patients with acromegaly.
Trainer PJ
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
[TBL] [Abstract][Full Text] [Related]
38. Effect of different growth hormone (GH) mutants on the regulation of GH-receptor gene transcription in a human hepatoma cell line.
Deladoëy J; Gex G; Vuissoz JM; Strasburger CJ; Wajnrajch MP; Mullis PE
Eur J Endocrinol; 2002 Apr; 146(4):573-81. PubMed ID: 11916628
[TBL] [Abstract][Full Text] [Related]
39. The role of growth hormone-receptor antagonism in relation to acromegaly.
Ayuk J; Sheppard MC
Expert Opin Pharmacother; 2004 Nov; 5(11):2279-85. PubMed ID: 15500374
[TBL] [Abstract][Full Text] [Related]
40. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]